A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer.

A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer.

Future Sci OA. 2018 Feb;4(2):FSO266

Authors: Roumeguère T, Legrand F, Rassy EE, Kaitouni MI, Albisinni S, Rousseau A, Vanhaeverbeek M, Rorive S, Decaestecker C, Debeir O, Boudjeltia KZ, Aoun F

Abstract
Aim: We evaluated the relationship between IL-8 and prostate cancer (PCa) with emphasis on diagnosis, aggressiveness and prognosis.
Materials & methods: Prostate-specific antigen (PSA) and serum IL-8 were collected from patients undergoing prostate biopsy. IL-8 expression was evaluated on immunohistochemistry with IL-8 labeling index. Complete follow-up of this cohort was achieved over a period of up to 6 years with continuous follow-up of PSA levels.
Results: Among 135 patients, serum IL-8 level did not correlate to the diagnosis or aggressiveness of PCa. In 52 radical prostatectomy specimens, a higher IL-8 labeling index was detected in the tumor areas (0.4 ± 0.2 vs 0.33 ± 0.2; p = 0,007) but did not correlate to any of the prognostic markers: D'Amico classification (p = 0.52), Gleason score (p = 0.45), perineural (p = 0.83) and capsular invasion (p = 0.75). No correlation was found to PSA biochemical-free failure.
Conclusion: IL-8 serum level was not a significant predictor of diagnosis, aggressiveness or prognosis of PCa.

PMID: 29379640 [PubMed]

from #PM All via ola Kala on Inoreader http://ift.tt/2rVq5az